Terms & Conditions of use

Notice & Disclaimer -  Important – Read This Carefully

The use of this web site is subject to the following conditions. IF YOU DO NOT WISH TO ABIDE BY OR BE BOUND BY THESE CONDITIONS THEN UNDER NO CIRCUMSTANCES SHOULD YOU ACCESS OR USE THIS WEB SITE AND YOU SHOULD EXIT THIS WEB SITE IMMEDIATELY. BY USING THIS WEB SITE YOU AGREE TO BE LEGALLY BOUND BY THESE CONDITIONS AND THE TERMS OF DISCLAIMERS CONTAINED IN THESE CONDITIONS.

Access to this Web Site and disclaimer

This web site is operated by Apitope International NV from the UK. Apitope makes no representation that any information or material contained on this site is suitable or appropriate for use in any other jurisdiction. Accordingly, if you access this web site from any jurisdiction outside the UK, you accept that you are responsible for compliance with all applicable laws.

Apitope makes no representation or warranty as to the availability or access to this web site. The information and materials supplied on this web site are provided on an ‘as is’ and “as is available” basis without warranty of any kind and are subject to change, removal, or restrictions to access without notice. Apitope makes no representation about the completeness or accuracy of such information and materials or that they are up to date or free from viruses. To the extent permissible by law, in no event, including but not limited to negligence, shall Apitope be liable for any direct, indirect, special, punitive, consequential, incidental or other damages or loss of profits arising from or related to the use, or inability to use, this web site, the information and/or materials contained in this web site or any information or materials on any web site linked to this web site.

Should Apitope incur any liability to you in relation to your access to or use of this web site or information available on or via it, such liability shall be limited in respect of all damages, losses and causes of action of whatever nature, including but not limited to negligence, to the amount, if any, paid by you to gain access to this web site.

Links to other web site

This web site may contain links to other web sites and to material contained on other web sites. Apitope is not responsible for the content or availability of such other web sites and to the extent permitted by law disclaims all liability in respect of such content and web sites and any content which may be accessed from such web sites. Please note Apitope is not responsible for the privacy practices of other web sites and the privacy statement below applies only to information collected by this web site.

Intellectual Property

Apitope has developed this web site, and except as otherwise expressly stated, the copyright and database rights in this web site and its contents are owned by Apitope. No part of this web site may be published, distributed, extracted, re-utilized or reproduced in any material form (including photocopying or storing in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) except with the express permission of Apitope or as permitted by the Copyright Designs and Patents Act 1988 or the Copyright and Rights in Databases Regulations 1997 as applicable.

Governing law

All matters relating to this web site shall be governed by UK law and by accessing this web site you submit to the exclusive jurisdiction of the UK Courts.

Latest News

  • Apitope to present at ECTRIMS 2019 Stockholm, Sweden

    Professor David Wraith Apitope’s founder and CSO and Dr Lotta Jansson, Chief Research Officer are scheduled to attend ECTRIMS 2019. The conference is being held in Stockholm Sweden between 11th-13th September ECTRIMS 2019 at the Stockholmsmässan. Professor Wraith will present during Session 12 entitled ‘Immunopathogenesis and antigen specific therapies’ details of which are below: 13 September 2019 Presentation: A future for antigen specific immunotherapy for multiple sclerosis Time: 08:50am Presenter: David Wraith

    Read More

  • Apitope Announces Publication of Data in International Peer-Reviewed Journal Thyroid on Graves’ disease Therapy

    HASSELT, Belgium, and CHEPSTOW, UK, 20 June 19 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces publication of its clinical Graves’ disease data in Thyroid, one of the leading peer-reviewed thyroid disease related medical journals. The publication entitled: Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study , reports the results from a first in human clinical study to assess the safety, tolerability and efficacy of Apitope’s antigen-specific immunotherapy, ATX-GD-59, in patients with Graves’ disease. The open-label trial reported in the paper was conducted in patients with mild to moderate Graves’ disease. These preliminary data suggest that ATX-GD-59 is a safe and well-tolerated treatment. The improvement in free thyroid function in 70% of subjects receiving the medication suggests potential efficacy as a novel treatment for Graves' hyperthyroidism. Hayley French, CEO of Apitope, said: “We are delighted that these data have been published in Thyroid, a peer-reviewed journal for thyroid related diseases. For people suffering from Graves’, the project’s progress has finally created hope that the underlying disease can be treated and, for the first time in over 70 years, an innovative disease modifying treatment could be on the horizon”. https://www.liebertpub.com/doi/full/10.1089/thy.2019.0036

    Read More

  • Apitope Announces Management Changes

    Keith Martin to retire as CEO, continue as Non-Executive DirectorHayley French appointed COO and interim CEO HASSELT, Belgium, and CHEPSTOW, UK, 24 October 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces that Chief Executive Officer (CEO) Dr Keith Martin has decided to retire from the CEO role after 12 years at the helm of Apitope. He will remain on the Apitope Board as a non-executive director. Dr Hayley French will move to Chief Operations Officer (COO) and act as interim CEO of Apitope until a permanent replacement is in place. Dr French will join the Board of Directors effective immediately. Dr French brings over 25 years of experience in the pharmaceutical and biotechnology industry, most recently as Chief Business Officer & General Counsel of Apitope and prior to this she spent three years at Novartis where she worked on all global deals and collaborations in the respiratory division. She has been with Apitope since November 2010 and has over twenty years’ experience of negotiating licences and collaborations and managing alliances in the life sciences sector. Stéphane Verdood, Chairman of the Board of Directors of Apitope, commented: “Keith’s contribution to Apitope’s growth during his 12-year tenure has been immeasurable. Under his strategic leadership Apitope has grown to be a clinical stage biotech with multiple programmes in development for diseases with high unmet needs. On behalf of the Board we would like to thank Keith for his contribution to Apitope and we are delighted he will stay on the Board as a Non-executive Director. “I am very pleased that Hayley has agreed to take on the role of COO and interim CEO to ensure the smooth running of the company. She has played a major role in Apitope’s growth and success over the past eight years and the Board is confident in her expertise and experience in progressing Apitope’s growth and maximising the potential of its clinical programmes.” Dr Keith Martin said: “It has been an honour to have led Apitope and the transformation of the company from a University of Bristol spin-out to a clinical stage company with a strong clinical pipeline. I am proud of our achievements to date and I look forward to supporting the growth and development of Apitope as a Board member.” Dr Hayley French, newly appointed interim CEO of Apitope, added: " With efficacy demonstrated in two diseases, Apitope has a robust clinical pipeline of first-in-class antigen-specific immunotherapies for the treatment of autoimmune diseases. Apitope’s ATX-MS-1467 is a potential game changer in the treatment of multiple sclerosis and ATX-GD-59 appears to be the first disease-modifying treatment for Graves' disease in over 60 years. I look forward to maximising the potential of these important new treatments and lead the Company through its next phase of growth." Prior to joining Apitope, Dr French spent three years at Novartis and prior to this worked in the Life Sciences Group of Bird & Bird, London, specialising in advising pharmaceutical and biotech companies. Prior to joining Bird & Bird, she was Head of Commercial Legal Affairs at the Centre for Applied Microbiology and Research (CAMR) in Salisbury, UK. Dr French started her career at University College London Ventures where she was responsible for the development, management and commercialisation of technologies in the life sciences sector. She is past president of the Licensing Executives Society Britain & Ireland, and chair of the Licensing Executives Society International (LESI) life sciences committee. Dr French teaches on the LESI Intellectual Asset Management courses and is a regular speaker on IP licensing and negotiation. She has a B.Sc. in Microbiology from the University of Liverpool, as well as a PhD in Microbiology and a M.Sc. in intellectual property from the University of London and is a certified licensing professional (CLP).

    Read More

  • Apitope Announces Publication of Graves’ Disease Data in International Peer-Reviewed Journal, Endocrinology

    HASSELT, Belgium, and CHEPSTOW, UK, 14 August 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces publication of its pre-clinical Graves’ disease data in Endocrinology, one of the leading peer-reviewed endocrinology medical journals. The publication entitled: Immunotherapy with apitopes® blocks the immune response to thyroid stimulating hormone receptor in HLA-DR transgenic mice , reports the results from a series of studies to identify peptides that can be used to treat the abnormal immune response to TSHR (thyroid stimulating hormone receptor) in Graves’ disease patients and can be found here. The study showed that a mixture of two immunodominant apitopes® was sufficient to suppress both the abnormal T cell and antibody response to TSHR in HLA-DR transgenic mice. Tolerance induction was not disrupted by current drug treatments for Graves’ disease. The paper concluded antigen-specific immunotherapy with apitopes® from TSHR is a suitable approach for the treatment of Graves’ disease. Dr Keith Martin, CEO of Apitope, said: “It is very encouraging to have these findings by our talented team of scientists published in Endocrinology, one of the most highly-regarded journals in the field. The data shows that immunotherapy with apitopes® is a suitable approach to be investigated for the treatment of Graves’ disease and demonstrate the potential to be the first disease-modifying treatment, as well as the first innovative therapy for Graves’ disease in more than 60 years.” Prof David Wraith, CSO of Apitope, said: “I am excited to see these data published because it provides further evidence of the broad applicability of the Apitope platform to identify peptide apitopes® to treat a wide range of autoimmune diseases. The initial clinical data announced earlier this year confirmed the potential for the apitopes® reported in this publication to make a significant impact in the treatment of Graves’ disease.”

    Read More